Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 10;9:1038114. doi: 10.3389/fcvm.2022.1038114

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 MacDonnell, Megna, Ruan, Zhu, Halasz, Jasewicz, Powers, E, del Pilar Molina-Portela, Jin, Zhang, Torello, Feric, Graziano, Shekhar, Dunn, Glass and Morton.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Activin A exposure time course on hiPSC-CM function. (A) The effect of different concentrations of Activin A on hiPSC-CM contractile impedance amplitude. (B,C) The impact of Activin A inhibition on Activin A–induced contractile dysfunction in hiPSC-CMs: dose-dependent effect on contractile impedance amplitude (B) and contractile parameters at both intrinsic and normalized beat rate (C). (D) Representative traces at both intrinsic beat rate and paced at 1 Hz hiPSC-CM, induced pluripotent stem cell-derived CM. Vertical lines indicate media changes in panels (A,B). One-way ANOVA was used to determine significance. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ActA, Activin A; CM, cardiomyocyte; hiPSC-CM, human-induced pluripotent stem cell-derived cardiomyocyte.